Active-ingredient Dossier
Pregabalin
Active-ingredient Dossier for Pregabalin (anticonvulsant analgesic). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: LYZALON
- Brand: ADIMEDI
- Brand: Pregabalin-AFT
- Brand: LYRICA
- Brand: ADIRAMEDICA
- Brand: ADRABALIN
- Therapeutic area: Neurology
What is
Pregabalin Pregabalin is an anticonvulsant analgesic.
Australian brands containing
Pregabalin — LYZALON — ADIMEDI — PREGACIPLIN — Pregabalin-AFT — LYRICA — ADIRAMEDICA — ADRABALIN — AKM-PREGABALIN — APO-PREGABALIN — LYRILIN — NEUROCCORD — PREBALIN
Therapeutic areas
Pregabalin is registered in neurology, with 39 brands containing the ingredient on the ARTG.
Sponsor landscape
The ingredient is marketed by 14 sponsors, including Arrotex Pharmaceuticals, AdiraMedica, Dr Reddys Laboratories, Cipla, Accord Healthcare, and Pharmacor.
PBS and regulatory activity
One brand with pregabalin has PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2020–21 fiscal year, pregabalin attracted government expenditure of approximately AUD 72.8 million across 3.26 million scripts. The latest PBAC outcome was recorded on 1 May 2022, with three brands having PBAC outcomes on record. The latest AusPAR was published on 9 June 2022, with one brand having an AusPAR on record.